**
A new injectable form of the immunotherapy drug Keytruda has been launched in the UK, potentially transforming the treatment experience for thousands of cancer patients. This advancement is expected to significantly reduce the time patients spend in hospitals, with the administration of the drug now taking mere minutes rather than the hour-long intravenous infusions previously required. With around 14,000 patients commencing treatment with Keytruda each year in England, this innovation could not only enhance patient comfort but also alleviate pressure on NHS resources.
A Revolutionary Treatment Approach
Keytruda, also known as pembrolizumab, has been a cornerstone in the treatment of various cancers since its introduction, including lung, cervical, and breast cancer. Traditionally administered via intravenous infusion, the process has been time-consuming and often exhausting for patients. However, the new injectable formulation drastically reduces the administration time to just one or two minutes, depending on the treatment schedule.
Shirley Xerxes, an 86-year-old patient from St Albans, was among the first to experience this new method at the Mount Vernon Cancer Centre near Watford. Reflecting on her experience, she remarked, “I was in the chair for a matter of minutes instead of an hour or more. It’s made such a difference and gives me more time to live my life, including spending more time gardening.”
The Impact on Patient Care
The introduction of the injectable Keytruda is set to enhance the overall treatment experience for patients. NHS England estimates that approximately 14,000 patients initiate Keytruda treatment annually, and the new format is expected to transition many of these individuals from lengthy infusion sessions to quick injections. The treatment will be administered every three weeks or every six weeks, tailored to the specific cancer diagnosis.
Professor Peter Johnson, NHS England’s national clinical director for cancer, emphasised the benefits of this change, stating, “Managing cancer treatment and regular hospital trips can be really exhausting. If we can do this in a much shorter period of time, it frees up space in our chemotherapy units and means we can start thinking about giving treatment in the community and away from hospitals.”
Financial Implications and Future Considerations
While NHS England has not disclosed the financial arrangements concerning the injectable Keytruda, it is believed that the cost to the health service will remain consistent with the existing infusion model. Keytruda is already one of the most commercially successful drugs globally, having generated estimated sales of $180 billion since its market launch more than a decade ago.
As the patents for Keytruda are set to expire in the coming years, there are concerns about competition from generic versions. Critics, including US Senator Elizabeth Warren, have voiced suspicions that the introduction of the injectable form is a strategy by Merck Sharp & Dohme (MSD) to maintain market dominance. In response, MSD highlighted the practical benefits of the new formulation, asserting that it will reduce the time spent administering the drug and enable healthcare providers to focus on other critical clinical tasks.
Why it Matters
The introduction of the injectable Keytruda represents a significant advancement in cancer treatment, with the potential to improve patient outcomes and streamline healthcare delivery. By minimising hospital visits and wait times, this innovation not only enhances the quality of life for patients but also optimises the use of NHS resources. As the healthcare landscape continues to evolve, such developments are vital for addressing the growing demands on the system and ensuring that patients receive timely and effective care.